Speech-Language Pathologists in Moonachie, NJ Accepting Medicare
1 Speech-Language Pathologists found. Showing 1 - 1
 Speech Within Reach, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 314 Maple St, Moonachie, NJ 07074 Phone: 201-956-0182 |
News Archive
Blogs recognize Global Handwashing Day
The following blog posts were published in recognition of Global Handwashing Day, observed annually on October 15.
Amped up health law debate creeps into presidential, congressional races
Mitt Romney raises his attack on the Democrats' health care law while GOP presidential candidate Rick Santorum assails Romney for championing the Massachusetts health law - and takes the fight to the steps of the Supreme Court.
Study demonstrates potential of FCPCs as new source for cartilage regeneration
The self-repair of injured cartilage is difficult for several reasons, foremost of which is the lack of blood supply to the tissue. Therapeutic efforts aimed at cartilage repair are often not optimal. Surgical repair techniques often lead to the formation of fibrocartilage, which is weaker and less durable. Although cell transplantation aimed at cartilage repair has been carried out using mesenchymal stem cells (MSCs), varying outcomes have resulted, despite the propensity of MSCs to proliferate and differentiate.
Markers in blood and spinal fluid, and a new imaging agent, show promise for early detection of Alzheimer's
With the continued aging of the population and the growing epidemic of Alzheimer's, early detection of the disease is crucial for risk assessment, testing new therapies, and eventual early intervention with better drugs, once they are developed. Four studies reported today at the Alzheimer's Association's 2008 International Conference on Alzheimer's Disease (ICAD 2008) in Chicago bring us closer to that goal of early detection by describing advances in biomarkers.
VYTORIN reduces major vascular events in patients with chronic kidney disease
In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)
› Verified 3 days ago